I received my master's degree in Biology from the University of Pisa in 2000 and my PhD in Molecular Biotechnology from the same university in 2004. I then moved to the University of Trieste where I worked as a postdoc until 2009 on a project aimed at characterizing the evolutionarily conserved interactome of the oncosuppressor p53. From winter 2009 to spring 2014, I worked at Beth Israel Deaconess Cancer Center and Harvard Medical School in Boston as a senior investigator first and instructor of medicine later, studying the oncogenic mechanisms of prostate cancer, their role in the response of cancer cells to standard oncologic approaches, and the establishment of innovative therapeutic strategies. In the summer of 2014, thanks to the Giovanni Armenise Harvard Foundation Career Development Award, I opened the Armenise-Harvard Laboratory of Cancer Biology and Genetics at the Department of Cellular, Computational and Integrative Biology -CIBIO- of the University of Trento. Since then, my group's research activity has focused on generating and studying sophisticated in vitro and in vivo models of human cancer onset, progression and resistance to therapies, with the ultimate goal of identifying reliable biomarkers and novel molecular targets for personalized, efficient and sustainable cancer treatment.